Biotech Day In Review: Novartis International AG Pulls Zelnorm Off The Market
Centient Biotech Investor submits: Novartis (NVS) suspended sales of Zelnorm, a treatment for irritable bowel syndrome with constipation, at the request of the FDA. The agency noticed a statistically significant number of cases of angina pectoris in patients taking the drug.